Friday, April 27, 2018
Innovus Pharmaceuticals, Inc., an emerging commercial-stage pharmaceutical company that delivers safe, innovative and effective over-the-counter medicine and consumer care products to improve men’s and women's health and respiratory diseases, today announced the launch of its lidocaine-based cream Xyralid®, for the relief of pain and symptoms caused by hemorrhoids. Xyralid® received a Product License Application (“PLA”) in Canada and the product is available as an over-the-counter (“OTC”) or behind the counter drug and will not require a prescription. The product is available in Canada directly through the Company’s website and through its Beyond Human® marketing and sales platform.
“We are very happy to announce the launch of Xyralid® in Canada,” said Dr. Bassam Damaj, the President and Chief Executive Officer of Innovus Pharma. “Xyralid® represents the second product launched through our own sales and marketing commercial efforts in Canada in addition to Apeaz® and is our sixth product on the Canadian market including Zestra®, Zestra Glide® and Uxor™ (EjectDelay™) marketed by Orimed Pharma and UriVarx® through our partnership with Acerus Pharmaceuticals Corporation.”
